drugset
drugset / Trial / NCT04577001

Letrozole in Patients With Hepatopulmonary Syndrome

NCT04577001 ↗

Phase 2 Terminated 1 enrolled Mayo Clinic University of California, San Francisco · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and possible benefit of letrozole compared to placebo in patients with Hepatopulmonary Syndrome.

Timeline

Start
2021-02-18
Primary completion
2021-03-26
Completion
2021-03-26

Outcome

Outcome not reported

Stopped (Enrollment): “Low Recruitment Numbers”

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications

hepatopulmonary syndrome